Biophytis SA

( )
BPTS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
ARGXargenx SE 1.38%379.000.0%$101.97m
VRXValeant Pharmaceuticals International, Inc. -1.96%6.7714.1%$39.84m
BRBRBellRing Brands, Inc. -0.55%23.730.0%$25.62m
RVMDRevolution Medicines, Inc. -1.60%21.520.0%$15.70m
USNAUSANA Health Sciences, Inc. 0.74%53.314.2%$3.49m
PRPHProPhase Labs, Inc. 2.35%10.440.1%$0.99m
CDXCChromadex Corp. 0.00%1.702.4%$0.61m
BVXVBiondVax Pharmaceuticals Ltd. 13.57%8.790.0%$0.39m
QLGNQualigen Therapeutics, Inc. -2.70%1.800.0%$0.34m
NATRNature's Sunshine Products, Inc. -0.33%8.980.4%$0.33m
UPXIUpexi, Inc. -0.74%4.050.0%$0.31m
IMCCIM Cannabis Corp. -7.49%2.100.0%$0.29m
BGXXBright Green Corp. 2.16%0.570.0%$0.25m
FLGCFlora Growth Corp. -3.62%0.480.0%$0.25m
PMCBPharmaCyte Biotech, Inc. -0.33%3.020.0%$0.19m

Company Profile

Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 15, 2006 and is headquartered in Paris, France.